EN DE
Watch SciBase Holding for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SciBase Holding (SCIB) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SciBase Holding stock SEK 10.02, price SEK 11.35, that is 11.7% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0007045414

SH SciBase Holding logo Thin data Nov 10, 2026

SciBase Holding

SCIB · ST
Expensive, weak quality

Our calculation puts a fair price 12% below what the stock costs today.

Revenue last quarter +74% vs. a year ago.
Expensive Growth (revenue 5y +33.6 %/yr in SEK)
Fair value kr 10.02 · Overvalued
Quality 30/100
Loss-making · -184.8% net margin (TTM)
High debt
Negative free cash flow
Trails peers (3/10)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch SciBase Holding for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 466.83 kr 11.15 Fair Value kr 10.02 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 11.15 – kr 466.83 · fair‑value band kr 7.52 – kr 12.53 · the kr 11.35 price screens above the kr 10.02 fair value. As of Nov 10, 2026.

Follow SciBase in your weekly email

Every Wednesday you see whether SciBase is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments.

Show moreShow less

The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment. It has a collaboration with Mayo Clinic on pigmented lesion digital workflows with AI-driven Nevisense.

SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.

Stock analysis

SciBase Holding (SCIB) currently trades at kr 11.35, while our estimate is kr 10.02, 12% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 7.52 (bear) to kr 12.53 (bull), the price of kr 11.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SciBase Holding reported revenue of 40.5M SEK in FY2025 versus 11.7M SEK in FY2021, a compound +36.3%/yr. Reported net income was −87.1M SEK in FY2025.

Key figures

Market cap 156M SEK (≈ $15.8M) Micro · P/S ratio 3.00 · EPS (TTM) kr −14.74 · Return on equity −310% · Return on assets (EBIT) −99.7% (5-year average) · Operating margin −188% · Revenue (TTM) 52.4M SEK · Revenue growth (YoY) +74.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −12%, SCIB screens richer than that median.

Fair Value

Bear kr 7.52 Fair Value kr 10.02 Bull kr 12.53
Price kr 11.35 · Downside -11.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 26
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.6%
Start year 2020 (pandemic). Over 10 years: +25.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−356.2% (2020) → −210.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SCIB screens overvalued: fair value 12% below the price. Compare with Abbott Laboratories, →

Compare SciBase Holding with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −11.7% · Above median
Profitability
Return on assets −166.9% · Bottom 25%
Net margin (12 months) −184.8% · Bottom 25%
Operating margin (12 months) −188.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 74.1% · Top 25%
Balance sheet
Debt / equity 3.01× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 23.45× · Priciest 25%
P/S (12 months) 2.98× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)18 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs SCIB
DexCom, Inc DXCM $79.92 $89.18 +12% vs SCIB
Stryker Corporation SYK $324.29 $358.30 +10% vs SCIB
STERIS plc STE $257.12 $279.53 +9% vs SCIB
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs SCIB
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs SCIB
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs SCIB
Abbott Laboratories, ABT $110.46 $75.28 −32% vs SCIB
Medtronic plc MDT $101.59 $65.61 −35% vs SCIB
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs SCIB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SciBase Holding: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SciBase Holding Fair Value". https://www.fairvalue-calculator.com/stock/SCIB

Frequently asked questions

Is SciBase Holding (SCIB) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 10.02 versus a price of kr 11.35, about 12% lower (overvalued).
What is the fair value of SCIB?
Our estimate for SciBase Holding is kr 10.02 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 11.35.
What is the quality score of SCIB?
SciBase Holding has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SciBase Holding (SCIB)?
Our calculated price target is the estimate of kr 10.02 (as of Nov 10, 2026). Cautious scenario kr 7.52, optimistic scenario kr 12.53. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SciBase Holding stock forecast for 2026?
Our estimate puts fair value at kr 10.02, about 12% lower versus a price of kr 11.35 (overvalued). Cautious scenario kr 7.52, optimistic scenario kr 12.53. The calculation is refreshed regularly with new filings.
What is the revenue of SciBase Holding (SCIB)?
SciBase Holding reported trailing-twelve-month revenue of about 52.4M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of SciBase Holding (SCIB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SciBase Holding it is kr 10.02 per share (as of Nov 10, 2026), against a price of kr 11.35.
Is SciBase Holding stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SCIB trades above its calculated fair value: price kr 11.35, fair value kr 10.02, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCIB?
No. The price is what the market pays today (kr 11.35); the fair value is what the company's own numbers justify (kr 10.02). For SciBase Holding the two are kr 1.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is SciBase Holding worth?
The market values SciBase Holding at about 156M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 11.35; our models calculate a fair value of kr 10.02 per share.
What do the bullish and bearish scenarios say about SCIB?
Our models span a range for SciBase Holding: cautious scenario kr 7.52, base kr 10.02, optimistic kr 12.53 per share (as of Nov 10, 2026, price kr 11.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SciBase Holding (SCIB)?
Balance-sheet figures for SciBase Holding (as of Nov 10, 2026): return on equity −309.8%, debt of 3.01 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is SCIB from its 52-week high?
SciBase Holding trades at kr 11.35, about 77% below its 52-week high of kr 49.25 and 2% above the low of kr 11.15 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 10.02 is for.
Which stocks are comparable to SciBase Holding?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SciBase Holding stock attractive at the current price?
The data as of Nov 10, 2026: price kr 11.35, calculated fair value kr 10.02 (−12%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. SciBase Holding itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SciBase Holding (SCIB)?
The closing price on Nov 10, 2026 was kr 11.35. Our estimate is kr 10.02, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SciBase Holding right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of SciBase Holding

How large is the market capitalisation of SciBase Holding (SCIB)?
The market capitalisation of SciBase Holding is 156M SEK (≈ $15.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SciBase Holding (SCIB)?
The price-to-sales ratio of SciBase Holding is 3.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SciBase Holding (SCIB)?
Earnings per share at SciBase Holding are kr −14.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SciBase Holding (SCIB)?
The return on equity (ROE) of SciBase Holding is −310% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SciBase Holding (SCIB)?
On an EBIT basis the return on assets of SciBase Holding is −99.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SciBase Holding (SCIB)?
The operating margin of SciBase Holding is −188% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SciBase Holding (SCIB)?
Revenue at SciBase Holding is growing +74.1% versus a year earlier (3y avg +31.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SciBase Holding (SCIB) generate?
The free cash flow of SciBase Holding is −84.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SciBase Holding (SCIB) carry?
The net debt of SciBase Holding is 425K SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SciBase Holding in the live analysis

One click puts SciBase Holding on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.